Meningococcemia Guidelines

Updated: Aug 13, 2019
  • Author: Mahmud H Javid, MBBS; Chief Editor: John L Brusch, MD, FACP  more...
  • Print
Guidelines

Advisory Committee on Immunization Practices Guidelines on Meningococcal B Vaccination

The guidelines on meningococcal B vaccination by the Advisory Committee on Immunization Practices (ACIP) are as follows: [97, 98]

  • Persons aged 10 years or older at increased risk for serogroup B meningococcal disease: In persons at increased risk for meningococcal disease and for use during serogroup B meningococcal disease outbreaks, 3 doses of MenB-FHbp should be administered at 0, 1-2, and 6 months to provide earlier protection and maximize short-term immunogenicity. However, if the second dose of MenB-FHbp is administered at an interval of 6 months or greater, a third dose does not need to be administered.
  • Adolescents and young adults aged 16-23 years: When given to healthy adolescents who are not at an increased risk for meningococcal disease, 2 doses of MenB-FHbp should be administered at 0 and 6 months. If the second dose of MenB-FHbp is administered less than 6 months after the first dose, a third dose should be administered at least 4 months after the second dose.
  • Recommendations for use of MenB-4C vaccine are unchanged.
  • The two MenB vaccines are not interchangeable, and the same product must be given for all doses in a series.
  • Either MenB vaccine may be given concomitantly with other vaccines appropriate for this age, but preferably at a different anatomic site.
  • Defer vaccination in women known to be pregnant or lactating unless the woman is at increased risk for serogroup B meningococcal disease and if her healthcare provider determines that the benefits of vaccination outweigh the potential risks.